Učitavanje...
Phase II study of sunitinib in men with advanced prostate cancer
Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods: Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were...
Spremljeno u:
| Glavni autori: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2009
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2674960/ https://ncbi.nlm.nih.gov/pubmed/19403935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp111 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|